Monopar Therapeutics Inc. Operating Lease Cost
Monopar Therapeutics Inc. (MNPR) reported Operating Lease Cost of $50.86 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2024-03-28
- Monopar Therapeutics Inc. operating lease, cost for the quarter ending 2022-12-31 was -$2.71K, a 120.13% decline year-over-year.
- Monopar Therapeutics Inc. operating lease, cost for the quarter ending 2022-09-30 was $14.06K, a 4.39% increase year-over-year.
- Monopar Therapeutics Inc. operating lease, cost for the quarter ending 2022-06-30 was $11.99K, a 17.68% decline year-over-year.
- Monopar Therapeutics Inc. operating lease, cost for the quarter ending 2021-12-31 was $13.46K.
- Monopar Therapeutics Inc. operating lease, cost for fiscal 2023 was $50.86K, a 47.73% increase from fiscal 2022.
- Monopar Therapeutics Inc. operating lease, cost for fiscal 2022 was $34.42K, a 37.37% decline from fiscal 2021.
- Monopar Therapeutics Inc. operating lease, cost for fiscal 2021 was $54.96K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $50.86K 10-K · filed 2024-03-28 | |||
| 2022-12-31 | -$2.71K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $11.35K derived: sum of 2 quarters · filed 2024-03-28 | $23.34K derived: sum of 3 quarters · filed 2024-03-28 | $34.42K 10-K · filed 2024-03-28 |
| 2022-09-30 | $14.06K 10-Q · filed 2022-11-10 | $26.05K derived: sum of 2 quarters · filed 2022-11-10 | $37.13K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $11.99K 10-Q · filed 2022-08-11 | $23.08K 10-Q · filed 2022-08-11 | ||
| 2021-12-31 | $13.46K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $26.93K derived: sum of 2 quarters · filed 2023-03-23 | $41.50K derived: sum of 3 quarters · filed 2023-03-23 | $54.96K 10-K · filed 2023-03-23 |
| 2021-09-30 | $13.47K 10-Q · filed 2022-11-10 | $28.04K derived: sum of 2 quarters · filed 2022-11-10 | $41.50K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $14.57K 10-Q · filed 2022-08-11 | $28.03K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |